Pd28-09 Abnormal Her2 and Her3 Signalling in Prostate Cancer: Potentials for Clinical Application.

Journal of Urology - Netherlands
doi 10.1016/j.juro.2016.02.396
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

Cancer Research
Cancer ResearchOncology
2008English

WNT Signalling and Prostate Cancer

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2005English

Development and Clinical Application of Anti-Her2 Monoclonal and Bispecific Antibodies for Cancer Treatment

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Inhibition of EGFR, HER2, and HER3 Signalling in Patients With Colorectal Cancer Wild-Type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): A Phase 2–3 Randomised Trial

Lancet Gastroenterology and Hepatology, The
HepatologyGastroenterology
2018English

Novel Agents That Downregulate EGFR, HER2, and HER3 in Parallel

Oncotarget
Oncology
2015English

HER2-HER3 Dimer Quantification by FLIM-FRET Predicts Breast Cancer Metastatic Relapse Independently of HER2 IHC Status

Oncotarget
Oncology
2016English

Positive Prognostic Value of HER2-HER3 Co-Expression and P-mTOR in Gastric Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Review: Mathematical Modeling of Prostate Cancer and Clinical Application

Applied Sciences (Switzerland)
InstrumentationMaterials ScienceFluid FlowEngineeringComputer Science ApplicationsProcess ChemistryTransfer ProcessesTechnology
2020English

Hedgehog Signalling in Androgen Independent Prostate Cancer

European Urology
Urology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy